Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer

Launched by KONG FANMING · Jun 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether adding electroacupuncture (a therapy where small electrical currents are applied through acupuncture needles) to a type of cancer treatment called immune checkpoint inhibitors can help people who have had surgery for early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combined approach can lower the chances of the cancer coming back, improve the effects of the immune treatment, and help patients live longer with a better quality of life.

People who might be eligible for this study are adults between 18 and 80 years old who have had surgery for stage II or IIIA/B NSCLC, have already received some chemotherapy after surgery, and do not have certain genetic mutations in their cancer. They should be in generally good health, able to take care of themselves, and willing to follow the study plan. Participants can expect to receive regular treatments including electroacupuncture alongside their standard immune therapy, and doctors will closely monitor their health and cancer progress. This study is important because it looks at combining traditional Chinese medicine with modern cancer treatments to find new ways to improve recovery and survival after lung cancer surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Non-tumor patients with stage Ⅱ, ⅢA, ⅢB (N2) non-small cell lung cancer diagnosed by pathology or cytology after surgery; (2) driver mutations negative patients; (3) Postoperative adjuvant chemotherapy was received for 1 to 4 cycles;(4)conforms to two qi syndrome of traditional Chinese medicine syndrome differentiation diagnosis of patients; (5) aged 18 to 80 years old; (6) expected lifetime \> 6 months; (7) ECOG 0 to 2 points; (8) patients willing to accept this solution treatment, adherence to the good.
• Exclusion Criteria:
• • (1) Patients with other malignant tumors in the past or at the same time within 5 years; (2) has a serious heart, liver and kidney damage, or other serious complications; (3) the R1, R2, need after resection, postoperative adjuvant radiotherapy patients; (4) with mental disorders; (5) has a variety of drug allergy, allergic constitution; (6) in pregnancy or lactation women.